New hope for the treatment of pancreatic cancer

Share This Post

Early diagnosis of pancreatic cancer is difficult and lacks specific drugs. Recently, researchers from France and Spain have discovered that a substance that has been used to treat anxiety can interfere with the development of pancreatic cancer.

Pancreatic cancer is one of the deadliest tumors. At present, treatment is generally carried out through general chemotherapy regimens. Nupr1 protein is an “intrinsically disordered protein”. As early as the 1990s, scientists pointed out that it is involved in the development of pancreatic cancer. Now, scientists have discovered molecules that can inhibit the activity of this protein.

Experts say that this study screened molecules that effectively inhibit Nupr1 activity from more than 1,000 drugs that have been approved for the treatment of various diseases. Through the combination of computer simulation and pharmacological test, it can be known that the molecule can interact with Nupr1 protein. In vitro experiments show that it can reduce the viability and metastasis ability of tumor cells, and completely inhibit the possibility of colony formation. The effective compound has been tested in animals to prove that it can prevent the development of the disease. This compound is trifluoperazine.

Trifluoperazine was previously used only as an antipsychotic drug in clinic, and it is now shown that its antitumor efficacy is very good. This study has changed the direction of pancreatic cancer treatment. Inhibiting Nupr1 may become a new therapeutic direction for the treatment of this cancer.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

After amazing growth of CAR T-Cell therapy what's next
CAR T-Cell therapy

After amazing growth of CAR T-Cell therapy: what’s next?

CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient’s T-cells to attack cancer cells, demonstrating remarkable success in hematologic cancers. Advances in genetic engineering, regulatory support, and investment are driving further expansion. Researchers are now tackling the challenges of applying this therapy to solid tumors, aiming to enhance efficacy and accessibility, marking a new era in personalized cancer therapy and immunotherapy.

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy